Rhinovirus Infections - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 48 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Rhinovirus Infections - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Rhinovirus Infections - Pipeline Review, H2 2016', provides an overview of the Rhinovirus Infections pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Rhinovirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rhinovirus Infections and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Rhinovirus Infections
- The report reviews pipeline therapeutics for Rhinovirus Infections by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Rhinovirus Infections therapeutics and enlists all their major and minor projects
- The report assesses Rhinovirus Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Rhinovirus Infections

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Rhinovirus Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Rhinovirus Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Rhinovirus Infections Overview 6
Therapeutics Development 7
Pipeline Products for Rhinovirus Infections - Overview 7
Pipeline Products for Rhinovirus Infections - Comparative Analysis 8
Rhinovirus Infections - Therapeutics under Development by Companies 9
Rhinovirus Infections - Therapeutics under Investigation by Universities/Institutes 10
Rhinovirus Infections - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Rhinovirus Infections - Products under Development by Companies 13
Rhinovirus Infections - Products under Investigation by Universities/Institutes 14
Rhinovirus Infections - Companies Involved in Therapeutics Development 15
AIMM Therapeutics B.V. 15
AstraZeneca Plc 16
Aviragen Therapeutics, Inc. 17
Biological Mimetics, Inc. 18
Boehringer Ingelheim GmbH 19
Novartis AG 20
Rhinovirus Infections - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
BNT-014 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
KR-22809 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Monoclonal Antibodies to Inhibit Viral 3C Protease for Human Rhinovirus Infections - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Monoclonal Antibody for Human Rhinovirus Infections - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
OBR-5340 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
PL-402 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Polymer for Viral Infections - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Recombinant Peptide for Rhinovirus Infection - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Small Molecule to Inhibit PI4KIII beta for Rhinovirus Infection - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Small Molecules to Inhibit 3C Protease for Rhinovirus Infection - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
vapendavir - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Rhinovirus Infections - Dormant Projects 44
Rhinovirus Infections - Product Development Milestones 45
Featured News & Press Releases 45
Mar 03, 2015: Biota Commences Dosing in Vapendavir SPIRITUS Phase 2b Trial 45
Mar 28, 2012: Biota Announces Positive Phase IIb Data In Asthma Patients With Human Rhinovirus Infection 45
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48

List of Tables

Number of Products under Development for Rhinovirus Infections, H2 2016 7
Number of Products under Development for Rhinovirus Infections - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Products under Investigation by Universities/Institutes, H2 2016 14
Rhinovirus Infections - Pipeline by AIMM Therapeutics B.V., H2 2016 15
Rhinovirus Infections - Pipeline by AstraZeneca Plc, H2 2016 16
Rhinovirus Infections - Pipeline by Aviragen Therapeutics, Inc., H2 2016 17
Rhinovirus Infections - Pipeline by Biological Mimetics, Inc., H2 2016 18
Rhinovirus Infections - Pipeline by Boehringer Ingelheim GmbH, H2 2016 19
Rhinovirus Infections - Pipeline by Novartis AG, H2 2016 20
Assessment by Monotherapy Products, H2 2016 21
Number of Products by Stage and Target, H2 2016 23
Number of Products by Stage and Mechanism of Action, H2 2016 25
Number of Products by Stage and Route of Administration, H2 2016 27
Number of Products by Stage and Molecule Type, H2 2016 29
Rhinovirus Infections - Dormant Projects, H2 2016 44